Exalenz Bioscience

One-step Urea Breath Test

Health Tech & Life Sciences
Acquired (Inactive) by Meridian Bioscience on May 2020 - closed due to acquisition

Company Overview

Snapshot

Founded in April 2006, Exalenz Bioscience operated with 11–50 employees, raising a total of $10.68M across four funding rounds. The company was acquired by Meridian Bioscience in May 2020.

Business overview

Exalenz Bioscience develops and commercializes systems that extract diagnostic information from subtle changes in patients' exhaled breath, leveraging its proprietary BreathID technology platform. The company's core technology enables medical specialists to identify and manage specific digestive and liver conditions with clinical precision and patient comfort. Its flagship product, BreathID Hp, is a clinically proven, accurate single-step urea breath test for diagnosing and monitoring H. pylori infection in adults. Exalenz Bioscience operates within the Health Tech & Life Sciences sector, focusing on medical technologies, diagnostics, and gastroenterology, serving healthcare providers, doctors, clinics, and laboratories.

Strategic signal

In February 2020, Meridian Bioscience signed a definitive agreement to acquire Exalenz Bioscience for $49M, adding Exalenz's state-of-the-art urea breath test diagnostics platform to its portfolio. This acquisition highlights the strategic value of non-invasive diagnostic technologies in the healthcare market and signals a consolidation trend for companies with proven, FDA-cleared diagnostic solutions.

Company Intelligence Q&A

What was a significant corporate development for Exalenz Bioscience in 2020?
In May 2020, Exalenz Bioscience was acquired by Meridian Bioscience. The definitive agreement for this acquisition was signed in February 2020 for $49M, integrating Exalenz's diagnostic platform into Meridian Bioscience's offerings.
When did Exalenz Bioscience receive FDA clearance for pediatric H. pylori testing?
In May 2018, Exalenz Bioscience received FDA clearance for pediatric Helicobacter Pylori testing, expanding the application of its BreathID technology.
What was the outcome of Exalenz Bioscience's clinical trial results in January 2018?
In January 2018, Exalenz Bioscience announced positive clinical trial results for the diagnosis of clinically significant portal hypertension in NASH patients, demonstrating the efficacy of its BreathID technology in liver applications.
Did Exalenz Bioscience pursue a public offering in 2018?
In June 2018, Exalenz Bioscience announced the confidential submission of a draft registration statement for an Initial Public Offering.
What was a key market expansion for Exalenz Bioscience in 2019?
In February 2019, Exalenz Bioscience received approval for commercial marketing in China for its BreathID® Hp Lab System, expanding its global reach for H. pylori detection.

External links